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Abstract  
Bioanalytical methods are used for the quantitative analysis of drugs and their metabolites in the biological 
media like saliva, urine, plasma, serum. Development and validation of bioanalytical method is important to 
understand the pharmacokinetics of any drug and/or its metabolites. Bioanalytical method development consists of 
three essential interrelated parts sample preparation, chromatographic separation and detection by using proper 
analytical method. Validation of a Bioanalytical method is the process by which it is established that the 
performance characteristics of the method meet the requirements for the intended Bioanalytical application. The 
validation is further divided into 3 segments full validation, partial validation, and cross validation each of which has 
its own purpose. This review describes mainly the various aspects for development of bioanalytical method and for 
the validation of bioanalytical methods. Also the Bioanalytical method transfer is also described.  
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1. Introduction  
Bioanalytical Methods are widely employed for 
the Quantitative analysis of the drugs and their 
metabolites in the biological matrix or media like saliva, 
urine, plasma, serum, etc also plays a significant role in 
the evaluation of bioavailability, bioequivalence, 
pharmacokinetics studies2. Chromatographic techniques 
like Gas chromatography, HPLC, LC-MS, GC-MS, 
Ligand binding assay, immunological and 
microbiological procedures used for the above purpose7. 
Bioanalytical method development is a process of 
creating procedure which allows the drugs and their 
metabolites to be identified and quantified in biological 
matrix or media. A compound can often be measured by 
several methods and the choice of analytical method 
involves many considerations, such as chemical 
properties of the analyte, concentrations levels, sample 
matrix, cost of the analysis, and speed of the analysis, 
quantitative or qualitative measurement, and precision 
required and necessary equipment. A suitable protocol 
should be made for method development and validation 
technique. To create a relevant Bioanalytical method, the 
experts should initially understand the rationale of trial 
so as to understand which analytical information is going 
to be employed, prerequisite of the method, and outcome 
of the results after complete conclusion of investigation. 
Method development consists of three essential 
interrelated parts sample preparation, chromatographic 
separation and detection by using proper analytical 
method4. AProperly validated Bioanalytical method for 
quantitative determination of drugs and their metabolites 
(analytes) plays quite important role in the effective 
performance of bioequivalence, pharmacokinetic and 
toxicokinetic studies.Mathematical models could help to 
develop the robust and selective method1. Bioanalytical 
method is necessary to construct a concentration-time 
profile. Chemical techniques are employed to measure 
the concentration of drugs in biological matrix, most 
often plasma. Validation of a Bioanalytical method is the 
process by which it is established that the performance 
characteristics of the method meet the requirements for 
the intended Bioanalytical application. These 
performance characteristics are expressed in terms of 
Bioanalytical method validation parameters the 
fundamental Bioanalytical method validation parameters 
include precision and accuracy, sensitivity, 
reproducibility, recovery and stability. However, the 
stability of the method can be determined by several 
methods including freeze and thaw method, short-term 
temperature stability study, long term stability and bench 
top stability. 
 
1.1 Sample collection and Preparation2: The 
biological media that contain the analyte are usually 
blood, plasma, urine, serum etc. Blood is usually 
collected from human subjects by vein puncture with a 
hypodermic syringe up to 5 to 7 ml (depending on the 
assay sensitivity and the total number of samples taken 
for a study being performed). The venous blood is 
withdrawn into tubes with an anticoagulant, e.g. EDTA, 
heparin etc. Plasma is obtained by centrifugation at 4000 
rpm for 15 min. About 30 to 50% of the original volume 
is collected.  The purpose of sample preparation is to 
clean up the sample before analysis and/or to concentrate 
the sample. Material in biological samples that can 
interfere with analysis, the chromatographic column or 
the detector includes proteins, salts, endogenous 
macromolecules, small molecules and metabolic 
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byproducts .A goal with the sample preparation is also to 
exchange the analyte from the biological matrix into a 
solvent suitable for injection into the chromatographic 
system. General procedures for sample preparation like 
liquid/liquid extraction, solid-phase extraction (SPE) and 
protein precipitation. 
 
a. Liquid/Liquid Extraction: It is based on the 
principle of differential solubility and partitioning 
equilibrium of the analytes between the aqueous and 
organic phases. It generally involves the extraction of 
analyte from one phase into another phase and the 
distribution of the analyte molecules between two 
immiscible phases. After extraction of analyte the 
organic layer is separated from aqueous phase and it is 
evaporated in presence of nitrogen gas so as to get the 
dry form of sample. Now-a-days traditional LLE has 
beenreplaced with advanced and improved techniques 
like liquid phase microextraction (LPME), single drop-
liquid phase micro extraction (DLPME) and supported 
membrane extraction (SME).2,4 
b. Solid –Phase Extraction:This technique isolates the 
analytes of interest from wide variety of matrices 
includes urine, blood, animal tissue, soil, and beverages. 
The separation of desired analyte depends upon its 
affinity towards stationary phase. Analyte which is 
retained on the stationary phase can then be eluted from 
the solid phase extraction cartridge with the appropriate 
solvent. This technique is based on the principle of 
partitioning of the analytes between two phases. Now-a-
days, SPE sorbent is packed between two fritted disks in 
the cartridge made up of polypropylene. The liquid 
phase is thus allowed to pass through the cartridge.  
Commercial solid phase extraction cartridge is a short 
inert plastic tube packed with an adsorbent, usually a 
reversed phase or an ion exchange resin. The particle 
size of the packing is often significantly larger than that 
used in LC columns to ensure a reasonable permeability 
Silica-base with chemically bonded functional groups or 
highly cross-linked polymers such as styrene 
divinylbenzene and polymethacrylate are generally used 
materials for preparation of solid phase cartridges.The 
general procedure for SPE is loading of a sample onto a 
SPE cartridge after conditioning with water and 
methanol and then washing of the sample solution 
containing the analyte or sample matrix (commonly used 
solvent is HPLC grade water or MILLIQ water) for 
removing any undesired components and then eluting 
out the desired analyte into a test tube. Solid phase 
extraction uses the same type of stationary phase as it is 
used in liquid chromatography columns.SPE technique is 
modified by solid phase microextraction.2, 4 
 
 
Fig1: Solid-Phase extraction Assembly9 
 
 
c. Protein Precipitation: Protein precipitation can be 
applied to extraction of plasma and blood samples. 
Principle of PP is based on precipitation (denaturation) 
of the proteins by using various reagents like acid 
(trichloroacetic acid and perchloric acid), organic 
solvents (methanol, acetone and acetonitrile) or by salts 
(ammonium sulphate). After denaturation the sample is 
centrifuged, which results in extraction of analyte in the 
precipitating solvent. There are some benefits with the 
precipitation method as clean-up technique compared to 
SPE. It is less time consuming, smaller amounts of 
organic modifier or other solvents are used. The samples 
often contain protein residues and it is a non-selective 
sample cleanup method, there is a risk that endogenous 
compounds or other drugs may interfere in the LC-
system. However the protein precipitation technique is 
often combined with SPE to produce clean extract. 
Methanol is generally preferred solvent amongst the 
organic solvent as it can produce clear supernatant which 
is appropriate for direct injection into LC-MS/MS. Salts 
are other alternatives to acid and organic solvent 
precipitation. This technique is called as salt-induced 
precipitation. As the salt concentration of a solution is 
increased, proteinsaggregate and precipitate from the 
solution.2, 4 
 
2. Basics considerations for method development3: 
1. The choice of given method involves several 
considerations such as analytical concentration range i.e. 
required for the method, sample matrix, whether the 
measurement is qualitative or quantitative, precision 
required, equipment requirements, place of method 
implementation and availability of qualified personnel. 
2. The most important criteria during the method 
development is that the whole procedure, from sample 
collection to the analysis of the sample matrix, should be 
selective, simple and robust as possible so that the 
method could be implemented in an ordinary analytical 
lab without the purchase of highly expensive 
equipments. 
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3. Cost of analysis also plays an important role while 
developing a method for a particular analyte and also the 
method selected for the sample preparation. 
4. Also choice of sampling media plays an important. 
The most common samples obtained for bioanalysis are 
blood, plasma and urine. 
5. Separation or isolation of drugs and their metabolites 
is usually performed to purify a sample. This is done to 
obtain the selectivity and sensitivity to detect a particular 
compound and so as to reduce interference from the 
components of biological matrix. 
 
3. Method Validation2, 7, 5: 
The guidelines for bioanalytical method validation are 
published by the United States Food and 
DrugAdministration (USFDA) in May 2001. These 
guidelines are standard for validation parameters’ 
evaluation and requirements. Bioanalytical method 
validation is the approach employed to indicate that the 
analytical method used to assess an analyte in biological 
matrix is reliable and also reproducible.  There are three 
types of validations; full validation, partial validation, 
and cross validation.Method validation is a process used 
to verify/confirm that an analytic method developed is 
suitable for its intended purpose, that it provides reliable 
and valid data for a specific analyte. Typical parameters 
to validate are; include selectivity, accuracy, precision, 
linearity and range, limit of detection, limit of 
quantification, recovery, robustness and stability. 
Need For Bioanalytical Method Validation: 
1. for assurance of quality of products and formulations. 
2. Achieving and enhancing of products by international 
agencies. 
3. for compulsive requirement for registration of 
pharmaceutical product or formulations5. 
3.1 Full Validation: When carrying out bioanalytical 
method development of an analyte for the first time, 
fullmethod validation is employed. Full method 
validation is mandatory for any new drug entity. Also 
full method validation is recommended when 
metabolites are added to current assay of already existing 
analyte. The assay is required to be revised for all 
analytes measured. 
3.2 Partial Validation: Partial validations are usually 
modifications of validated bioanalytical methods which 
do not essentially require complete revalidations. In 
partial validation either one intra-assay of precision and 
accuracy is carried out or “approximately” full validation 
is done. Partial validation can also be carried out 
whenthere is alteration in species within matrix (e.g. rat 
plasma to mouse plasma), changes in matrix withina 
species (e.g., human plasma to human urine), change in 
analytical methodology (e.g., change in detection 
systems), change in sample processing procedure(s), 
change in anticoagulant in harvesting biological fluid. 
3.3 Cross Validation: Cross validation is comparison of 
two bioanalytical methods. Cross validations are 
essential when two or more bioanalytical methods are 
applied to generate information within same study. 
Theevaluations should be done by considering an 
innovative validated bioanalytical method as the 
reference and the repeated bioanalytical method as the 
comparator and vice-versa. 
a. Selectivity: Selectivity exercise is carried out to 
assess the ability of the bioanalytical method to 
differentiate and quantify the analyte(s) in presence of 
other components in the sample. For selectivity, analyses 
of blank samples of appropriate biological matrix 
(plasma, urine, or other matrix) obtained from at least six 
sources should be carried out. Each blank sample should 
be tested for interference and selectivity should be 
ensured at the lower limit of quantification (LLOQ). 
b. Accuracy: The accuracy of an analytical method 
describes the closeness of mean test results obtained by 
the method to the true value (concentration) of the 
analyte. Accuracy is determined by replicate analysis of 
samples containing known amounts of the analyte. 
Accuracy should be measured using a minimum of five 
determinations per concentration. A minimum of three 
concentrations in the range of expected concentrations is 
recommended. The mean value should be within 15% of 
the actual value except at LLOQ, where it should not 
deviate by more than 20%. The deviation of the mean 
from the true value serves as the measure of accuracy. 
c. Precision: The precision of an analytical method 
describes the closeness of individual measures of an 
analyte when the procedure is applied repeatedly to 
multiple aliquots of a single homogeneous volume of 
biological matrix. Precision should be measured using a 
minimum of five determinations per concentration. A 
minimum of three concentrations in the range of 
expected concentrations is recommended. The precision 
determined at each concentration level should not exceed 
15% of the coefficient of variation (CV) except for the 
LLOQ, where it should not exceed 20% of the CV. 
Precision is further subdivided into within-run, intra-
batch precision or repeatability, which assesses precision 
during a single analytical run, and between-run, 
interbatch precision or repeatability, which measures 
precision with time and may involve different analysts, 
equipment, reagents and laboratories. 
d. Linearity and Range: A calibration curve is the 
relationship between instrument response and known 
concentration of the analyte. The calibration curve 
should be prepared in the same biological matrix as the 
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samples and a calibration curve should be generated for 
each analyte. The range of the method is the 
concentration interval where accuracy, precision and 
linearity have been validated. The used calibration curve 
should be the simplest model that adequately describes 
the concentration-response relationship. The deviation 
should not exceed more than 20% from the nominal 
concentration of the LLOQ and not more than 15% from 
the other standards in the curve. 
e. Limit of Detection: The limit of detection (LOD) is a 
characteristic for the limit test only. It is the lowest 
amount of analyte in a sample that can be detected but 
not necessarily quantitated under the stated experimental 
conditions. The detection is usually expressed as the 
concentration of the analyte in the sample, for example, 
percentage, parts per million (ppm), or parts per billion 
(ppb). 
f. Limit of Quantification:Lower limit of 
quantification: LLOQ is the lowest amount of analyte in 
a sample that can be quantitatively determined with 
suitable precision and accuracy. Determining LLOQ on 
the basis of precision and accuracy is probably the most 
practical approach and defines the LLOQ as the lowest 
concentration of the sample that can still be quantified 
with acceptable precision and accuracy. LLOQ based on 
signal and noise ratio (s/n) can only be applied only 
when there is baseline noise, for example to 
chromatographic methods. Upper limit of quantification: 
ULOQ is the maximum analyte concentration of a 
sample that can be quantified, with acceptable precision 
and accuracy. The ULOQ is identical with the 
concentration of the highest calibration standards. 
g. Recovery: The recovery of an analyte in an assay is 
the detector response obtained from an amount of the 
analyte added to and extracted from the biological 
matrix, compared to the detector response obtained for 
the true concentration of the pure authentic standard. 
Recovery experiments should be performed by 
comparing the analytical results for extracted samples at 
three concentrations (low, medium, and high) with 
unextracted standards that represent 100% recovery. 
Recovery% = Extracted sample / Post-extraction spiked 
sample X 100 Recovery reflects the degree of extraction; 
in general recovery is impacted by the interaction of the 
analyte with endogenous and/or exogenous components 
of the matrix. 
h. Matrix Effect: Matrix effect is investigated to ensure 
that selectivity and precision are not compromised 
within the matrix screened. Three blank samples from 
each of at least six batches of matrix under screening are 
extracted. For matrix effect LQC (lower quality control), 
MQC (middle quality control) and HQC (higher quality 
control) spiking dilutions and internal standard dilution 
are spiked in the above extracted blank samples. 
Recovery comparison sample at LQC, MQC and HQC 
concentration level along with internal standard are 
prepared and screened. 
i. Robustness: According to ICH guidelines, The 
robustness of an analytical procedure is the measure of 
its capacity to remain unaffected by small, but deliberate 
variations in method parameters and provides an 
indication of its reliability during normal usage. 
Robustness can be described as the ability to reproduce 
the (analytical) method in different laboratories or under 
different circumstances without the occurrence of 
unexpected differences in the obtained result(s), and a 
robustness test as an experimental set-up to evaluate the 
robustness of a method. 
j. Stability: The stability of the analyte under various 
conditions should also be studied during method 
validation. The conditions used in stability experiments 
should reflect situations likely to be encountered during 
actual sample handling and analysis. The following 
stability conditions are required by FDA and are 
advisable to investigate;  
Stock solution stability: The stability of the stock 
solution should be evaluated at room temperature for at 
least 6 hours.  
Short-term temperature stability: The stability of the 
analyte in biological matrix at ambient temperature 
should be evaluated. Three aliquots of low and high 
concentration should be kept for at least 24 hours and 
then analysed.  
Long-term temperature stability: The stability of the 
analyte in the matrix should exceed the time period from 
sample collection until the last day of analysis.  
Freeze and thaw stability: The stability of the analyte 
should be determined, after three freeze and thaw cycles. 
Three aliquots of low and high concentration should be 
frozen for 24 hours and then thawed at ambient 
temperature.  
Post-preparative stability: The stability of the analyte 
during stages of the analysis processshould be evaluated. 
Bench-Top Stability: Bench top stabilityexperiments 
should be designed and conducted to cover the 
laboratory handling conditions that are expected for 
study samples. 
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Processed Sample Stability: The stability of processed 
samples, including the time until completion of analysis, 
695 should be determined. 
Method transfer10: Timely method transfer plays an 
important role in expediting drug candidates 
through development stages. Method transfer is not an 
easy task and requires careful planning and constant 
communication between the laboratory personnel 
involved in the transfer. Method transfer could occur 
within the same organization or between pharmaceutical 
companies and analytical service providers. To have a 
successful transfer, the bioanalytical method itself must 
be robust and the equipment differences between the 
delivering and receiving parties should be carefully 
evaluated. Use of standardized automation equipment 
has shown to be advantageous during the 
method transfer. 
 
4. Conclusion 
This review describes the various aspects for 
the bioanalytical method development and its validation. 
Bioanalytical method development consists of three 
essential interrelated parts sample preparation, 
chromatographic separation and detection by using 
proper analytical method. Validation of a Bioanalytical 
method is the process by which it is established that the 
performance characteristics of the method meet the 
requirements for the intended Bioanalytical application. 
Also the basic considerations for the method 
development are also discussed here. The development 
of bioanalytical method and its validation helps to 
determining the pharmacokinetics of drugs and their 
metabolites. For the method transfer the bioanalytical 
method must be robust and rugged also constant 
communication between the laboratory personnel 
involved in transfer is required.   
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